Nanomedicins and Biomedical engineering
Our research team makes the unique bridge between medical engineering, pharmaceutical nanotechnology and biomedical research by combining unique techniques, such as microfluidic glass technology, to help to build innovative nanomedicines/nanovectors and multidrug loading. To design and test the functionality and efficacy of these nanomedicines, we use state-of-the-art nanotheranostic technologies for personalized medicine, which allow the precisely engineering of materials at nanoscale to develop novel therapeutic formulations, including industrial scale-up validation, batch-to-batch reproducibility, and controllability of the nanomaterials’ physicochemical properties for translation into the clinic.
Hélder A. Santos, Unit Leader

Focusing on the development of nanoparticles/nanomedicines for biomedical and healthcare applications. We make the bridge between biomedical engineering and pharmaceutical. We use biodegradable and biocompatible nanoporous silicon nanomaterials and polymeric nanoparticles, together with the microfluidic technology for production of advance nanomedicines for simultaneous controlled drug delivery, diagnostic and treatment of cancer, diabetes, and cardiovascular diseases, and for further translation of these nanotechnologies into the clinic.

Jouni Hirvonen

Developing novel biomaterials for pharmaceutical technology applications, and controlled/targeted nanotechnology approaches for drug delivery systems. We focus on the drug delivery via the oral, cutaneous and pulmonary routes, as well as parenteral (targeted, precisely dosed drug delivery) administration routes of nanopharmaceutics.

Wei Li, postdoc

Wei Li is a postdoc in our group. He is working on microfluidics to develop drug delivery systems for oral administration and tissue engineering applications. Wei studied Biomaterials at the University of Erlangen-Nuremberg and obtained his PhD degree in 2015.

Dongfei Liu

Well-versed in a variety of fields, such as controlled drug delivery, nanomedicine and microfluidics. Primarily, we are interested in engineering optimal drug delivery systems by microfluidic techniques. For example, by exploiting superfast time intervals between sequential nanoprecipitation processes, we have produced structured nanocomposites. These nanocomposites harness the inherent ultrahigh drug loading degree and enhanced payload dissolution kinetics of drug nanocrystals and the controlled drug release from polymer-based nanoparticles. Beyond the engineering of optimal nanocomposites, we focus on their biomedical applications, such as cancer targeting drug delivery and spinal cord injury therapy.